Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
- Mechanism
- Curator reviewed
Like protease inhibitors, PA-1050040 and other maturation inhibitors interfere with protease processing of newly translated HIV polyprotein precursor, called gag. This molecule contains a number of HIV proteins in a single polypeptide which is then cleaved by the enzyme protease to produce functional structural proteins. However, unlike the protease inhibitors, PA-1050040 binds the gag protein, not protease. Once bound to gag, PA-1050040 prevents a critical cleavage at a site called the capsid-SP1 junction. The resulting virus particles lack functional capsid protein and have structural defects, rendering them incapable of infecting other cells. For reasons not entirely understood, protease inhibitor-resistant HIV-1 was hypersensitive to PA-1050040 in vitro.
- Primary indication
- Investigated for use/treatment in HIV infection.Curator reviewed
- Code names
- PA-1050040
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with PA-1050040, and which of those have an active Phase 3 trial?